Nanobodies, megapayoff
Enlarge image


Nanobodies, megapayoff

04.10.2012 - Belgian Ablynx secures €8.5m upfront from Merck Inc. for the development of Nanobodies against two targets, one of them yet unknown.

Camelidae antibody developer Ablynx NV (Ghent) has inked a collaboration with US pharma major Merck & Co. Inc (MSD). The companies collaborate primarily to develop and commercialise Nanobody® candidates directed towards a certain voltage-gated ion channel. Merck also acquired the option to do the same for a second, as yet unknown, target. The deal includes a €6.5m upfront payment and another €2m compensation for research funding. With successfully passed regulatory and commercial milestones in addition to secured royalties, Ablynx will be eligible to receive up to €448 million in total. While Ablynx is in charge of the discovery of the Nanobodies, Merck gains the exclusive global rights to market them and is responsible for research, development, manufacturing and commercialisation of any Nanobody® product resulting from the collaboration. 

After Ablynx showed the proof-of-principle in 2011, things are going well for the company despite the withdrawal of US pharma giant Pfizer almost a year ago. Edwin Moses, Chairman and CEO of Ablynx commented on the new deal: "We are delighted to initiate this collaboration with Merck in the area of ion channels, where to date, monoclonal antibodies have demonstrated little success. Due to the formatting flexibility of Nanobodies, we are able to combine antibody-like selectivity and multi-specificity in one molecule, making them ideal candidates for ion channel modulators." Nanobodies® are a novel class of therapeutic proteins based on single-domain, heavy-chain antibody fragments. They link conventional monoclonal antibody advantages like high specificity with the benefits of small molecule drugs like low sensitivity to temperature and pH changes. So far, Ablynx has approximately 25 programmes in the pipeline, and seven Nanobodies at clinical development stage, including partnerships with pharma and biotech companies like Boehringer Ingelheim (cancer, Alzheimer’s), former Merck Serono (osteoarthritis), Novartis, and Merck & Co.



12.10.2015 Aberdeen University spinout TauRx has picked up US$135m from a VC financing round. The biopharma company plans to bring its dementia hopeful through Phase III trials.


09.10.2015 The US pricing controversy is reverberating halfway across the globe. Shield Therapeutics has taken its IPO plans off the table. Market conditions are too volatile, the company says.


07.10.2015 T-cell specialist Adaptimmune Therapeutics plc needs more space for its R&D in immuno-oncology. The expanding UK company is building a major facility that will house 200 staff.

Drug DiscoveryGermany

06.10.2015 Evotec has been hired by the US National Cancer Institute (NCI) to provide compound management services to the Chemical Biology Consortium. The goal: the discovery of new cancer treatments.

Drug DevelopmentUKBelgium

01.10.2015 Autoimmune disease specialist Apitope has raised €12m in a Series B financing round and is relocating its UK headquarters to Wales.

Drug DevelopmentFranceEUFinlandSpainItalyAustria

01.10.2015 Paris-based BEAM Alliance, a network of companies working on novel antibiotics founded earlier this year, has released its first position paper.


29.09.2015 Swiss CNS specialist Asceneuron SA has raised CHF30m (€27.5m) in a Series A financing, winning Paris-based Sofinnova Partners as its largest investor.


28.09.2015 US company Aduro Biotech has acquired Dutch monoclonal antibody discovery and development firm BioNovion for €29m plus milestones.


24.09.2015 Nutrition company Nestlé is teaming up with biopharmaceutical company AC Immune SA to develop a Tau diagnostic assay for early Alzheimer’s.


22.09.2015 Bayer has taken another step in its restructuring and development as a life sciences company after splitting from all its chemical divisions.


All Events

Current issue

All issues

Product of the week


Stock list

All quotes


  • ZELTIA (E)4.12 EUR22.99%
  • PHARMING (NL)0.32 EUR10.34%
  • PLETHORA (UK)3.12 GBP8.33%


  • THERAMETRICS (CH)0.03 CHF-25.00%
  • BAVARIAN NORDIC (D)35.60 EUR-8.48%


  • OREXO (S)65.00 SEK40.4%
  • ZEALAND PHARMA (DK)160.00 DKK31.1%
  • THROMBOGENICS (B)3.98 EUR30.1%


  • THERAMETRICS (CH)0.03 CHF-50.0%
  • GALAPAGOS (B)38.68 EUR-25.8%


  • KARO BIO (S)41.90 SEK5137.5%
  • CHRONTECH PHARMA (S)0.34 SEK466.7%
  • GALAPAGOS (B)38.68 EUR247.8%


  • NEOVACS (F)0.75 EUR-76.1%
  • BIOTEST (D)19.54 EUR-72.9%
  • EVOCUTIS (UK)0.15 GBP-68.7%

No liability assumed, Date: 12.10.2015